{"id":3092,"date":"2026-08-24T04:31:42","date_gmt":"2026-08-24T04:31:42","guid":{"rendered":"https:\/\/valutednews.com\/?p=3092"},"modified":"2026-08-24T04:31:42","modified_gmt":"2026-08-24T04:31:42","slug":"ultragenyx-regeneron-merck-moderna-readout-newsletter","status":"publish","type":"post","link":"https:\/\/valutednews.com\/?p=3092","title":{"rendered":"Ultragenyx, Regeneron, Merck, Moderna: Readout Newsletter"},"content":{"rendered":"
<\/div>

<\/p>\n

\n

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n

Today, we talk more about Merck and Moderna\u2019s potentially field-changing cancer vaccine, see a couple FDA approvals, and learn more about the new FDA commissioner\u00a0nominee. Plus, brain organoids have stayed alive \u2014 and continue to mature \u2014 in a Harvard lab for five years.<\/p>\n

I wonder, actually,\u00a0about the\u00a0poor little brain organoids in Megan\u2019s story. Just pulsing in their Petri dishes, contemplating moral relativity or migraines. It\u2019s all very Robin Cook.<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t